ZEGFROVY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEGFROVY (ZEGFROVY).
ZEGFROVY is a monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR), blocking ligand binding and receptor dimerization, thereby inhibiting downstream signaling pathways involved in cell proliferation and survival.
| Metabolism | ZEGFROVY is a monoclonal antibody; metabolism is expected to involve catabolism into small peptides and amino acids via general protein degradation pathways. |
| Excretion | Primarily renal excretion of unchanged drug (65-75% of administered dose) and biliary/fecal elimination (20-30%), with less than 5% metabolized. |
| Half-life | Terminal elimination half-life is 18-24 hours in patients with normal renal function (CrCl ≥90 mL/min), allowing once-daily dosing. Half-life extends to 40-50 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 98% bound to serum albumin (primarily) and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.25 L/kg (approximately 10-18 L in a 70 kg adult), indicating limited extravascular distribution and high plasma protein binding; low Vd suggests minimal tissue penetration. |
| Bioavailability | Oral: 88-92% (with high-fat meal increases AUC by 30%; take consistently with or without food). Intravenous: 100%. |
| Onset of Action | Oral: 2-4 hours for detectable serum concentrations; clinical effect (e.g., peak glucose-lowering) observed by 4-6 hours. Intravenous: immediate (within 5-10 minutes for hemodynamic effects). |
| Duration of Action | Oral: 24-30 hours with sustained therapeutic effect, supporting once-daily dosing. Clinical duration aligns with half-life and dosing interval; in renal impairment, duration prolongs up to 72 hours. |
| Molecular Weight | 435.5 |
400 mg intravenously every 4 weeks
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for any degree of renal impairment, including end-stage renal disease on dialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | No specific dose adjustment required; consider renal function and monitoring for adverse effects due to age-related comorbidities. |
| 1st trimester | Avoid use in first trimester unless benefit outweighs risk; limited human data, animal studies show teratogenicity at high doses. |
| 2nd trimester | Use only if clearly needed; may cause fetal harm based on animal data. |
| 3rd trimester | Avoid near term due to risk of neonatal adverse effects (e.g., hypotension, renal impairment). |
Clinical note
Comprehensive clinical and safety monograph for ZEGFROVY (ZEGFROVY).
| Placental transfer | Crosses placenta in humans; fetal plasma concentrations approximately 50-100% of maternal levels. |
| Breastfeeding | Not recommended during breastfeeding; excreted in human milk, potential for serious adverse reactions in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ZEGFROVY or any componentConcurrent use with strong CYP3A4 inhibitorsSevere hepatic impairment (Child-Pugh C)
| Precautions | Infusion-related reactions including hypersensitivity and anaphylaxis, Interstitial lung disease (ILD) or pneumonitis, which may be fatal, Dermatologic toxicity including severe rash, exfoliative dermatitis, and Stevens-Johnson syndrome, Electrolyte abnormalities such as hypomagnesemia and hypokalemia, Ocular toxicity including keratitis and ulcerative keratitis, Embryo-fetal toxicity: can cause fetal harm when administered to pregnant women |
| Food/Dietary | No known food interactions. Avoid grapefruit juice if taking concomitant medications metabolized by CYP3A4, as ZEGFROVY may inhibit this enzyme. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Associated with major congenital malformations including neural tube defects and craniofacial anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios. |
| Fetal Monitoring | Maternal: Renal function (serum creatinine, BUN, urine protein), blood pressure, liver function tests. Fetal: Serial ultrasound for growth and amniotic fluid volume, fetal Doppler studies. |
| Fertility Effects | Reversible reduction in sperm count and motility in males. Females: May cause anovulation and menstrual irregularities; fertility may return upon discontinuation. |
| Clinical Pearls | ZEGFROVY (fictitious drug) is a monoclonal antibody targeting IL-6 receptor. Use with caution in patients with active infections; hold if severe infection occurs. Monitor neutrophil counts, platelets, and liver enzymes. Avoid live vaccines during therapy. May require dose adjustment in renal impairment (CrCl <30 mL/min). Not recommended in pregnancy (Category C). |
| Patient Advice | Report signs of infection (fever, chills, sore throat) immediately. · Do not receive live vaccines (e.g., MMR, varicella) during treatment. · Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. · Take exactly as prescribed; do not miss doses or stop without consulting your doctor. · You may be at increased risk for allergic reactions; seek emergency care if you experience hives, difficulty breathing, or swelling. |